An open-label, Phase I study of cediranib (RECENTIN) in patients with acute myeloid leukemia.
Standard
An open-label, Phase I study of cediranib (RECENTIN) in patients with acute myeloid leukemia. / Fiedler, Walter; Mesters, Rolf; Heuser, Michael; Ehninger, Gerhard; Berdel, Wolfgang E; Zirrgiebel, Ute; Robertson, Jane D; Puchalski, Tom A; Collins, Barbara; Jürgensmeier, Juliane M; Serve, Hubert.
in: LEUKEMIA RES, 2009.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - An open-label, Phase I study of cediranib (RECENTIN) in patients with acute myeloid leukemia.
AU - Fiedler, Walter
AU - Mesters, Rolf
AU - Heuser, Michael
AU - Ehninger, Gerhard
AU - Berdel, Wolfgang E
AU - Zirrgiebel, Ute
AU - Robertson, Jane D
AU - Puchalski, Tom A
AU - Collins, Barbara
AU - Jürgensmeier, Juliane M
AU - Serve, Hubert
PY - 2009
Y1 - 2009
N2 - VEGFR and c-Kit signaling pathways may contribute to the pathophysiology of acute myeloid leukemia (AML). Thirty-five patients with AML received cediranib (RECENTIN), an oral, highly potent VEGF signaling inhibitor with c-Kit activity, at doses of
AB - VEGFR and c-Kit signaling pathways may contribute to the pathophysiology of acute myeloid leukemia (AML). Thirty-five patients with AML received cediranib (RECENTIN), an oral, highly potent VEGF signaling inhibitor with c-Kit activity, at doses of
M3 - SCORING: Zeitschriftenaufsatz
JO - LEUKEMIA RES
JF - LEUKEMIA RES
SN - 0145-2126
ER -